Citation Impact
Citing Papers
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
2013
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials
2016
Pleiotropic effects of type 2 diabetes management strategies on renal risk factors
2015
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Myeloid-derived suppressor cells coming of age
2018 Standout
Defining the proteolytic landscape during enterovirus infection
2020 StandoutNobel
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
2016 Standout
Obesity, pregnancy, inflammation, and vascular function
2010
Chronic inflammation in the etiology of disease across the life span
2019 Standout
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review
2011
Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?
2008
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
2013
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
2017 Standout
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
2015 Standout
Preservation of β-Cell Function: The Key to Diabetes Prevention
2011
A position statement on NAFLD/NASH based on the EASL 2009 special conference
2010
β-Cell function in type 2 diabetes
2014
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
2013
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015 Standout
Subcutaneous adipose tissue exerts proinflammatory cytokines after minimal trauma in humans
2007
Glucose dysregulation and hepatic steatosis in obese adolescents
2009
Enteroviruses: Classification, diseases they cause, and approaches to development of antiviral drugs
2017
Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
2016
Maternal and child undernutrition and overweight in low-income and middle-income countries
2013 Standout
Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications
2009 Standout
Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
2013 Standout
Incretin-Based Therapies: Review of Current Clinical Trial Data
2010
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors
2010
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
2010
Thiazolidinediones and the liver in humans
2009
Overview of Newer Agents: Where Treatment Is Going
2010
Regulation of Ferroptotic Cancer Cell Death by GPX4
2014 Standout
Non-alcoholic fatty liver disease
2021 Standout
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
2012
Epidemiology and Natural History of Non-Alcoholic Steatohepatitis
2009
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
2012
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
2015 Standout
Insulin action and resistance in obesity and type 2 diabetes
2017
Type 2 diabetes
2017 Standout
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
2017 Standout
Brain Cell and Tissue Recovery in Rats Made Deficient in n-3 Fatty Acids by Alteration of Dietary Fat
1989 StandoutNobel
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
2013
Type 1 diabetes
2013 Standout
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
2010 Standout
Intracellular Lipid Accumulation in Liver and Muscle and the Insulin Resistance Syndrome
2008
The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function
2017 Standout
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
Characterizing the profile of obese patients who are metabolically healthy
2010
What We Talk About When We Talk About Fat
2014 Standout
Noninvasive Differentiation of Simple Steatosis and Steatohepatitis by Using Gadoxetic Acid–enhanced MR Imaging in Patients with Nonalcoholic Fatty Liver Disease: A Proof-of-Concept Study
2014
Type 2 diabetes mellitus
2015 Standout
Cardiovascular Effects of Glucagonlike peptide–1 Agonists
2011
The key roles of elongases and desaturases in mammalian fatty acid metabolism: Insights from transgenic mice
2009
Adipose tissue macrophages: going off track during obesity
2016
Prediabetes: a high-risk state for diabetes development
2012 Standout
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis
2010
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Adipose Tissue as an Endocrine Organ
2004 Standout
An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases
2007 Standout
Slow Virus Replication: the Role of Macrophages in the Persistence and Expression of Visna Viruses of Sheep and Goats
1982
Restricted Adipogenesis in Hypertrophic Obesity
2013
Pathophysiology of Human Visceral Obesity: An Update
2013 Standout
Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
2013
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
2009 Standout
Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in J apanese patients (LEAN ‐J )
2014
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the E fficacy and D urability of I nitial C ombination T herapy for T ype 2 D iabetes ( EDICT ): a randomized trial
2014
The Role of Mononuclear Phagocytes in HTLV-III/LAV Infection
1986 StandoutScience
Causes and Metabolic Consequences of Fatty Liver
2008
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Personalized Management of Hyperglycemia in Type 2 Diabetes
2013
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
2014 Standout
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
2016
Nonalcoholic Fatty Liver Is Not Associated with Carotid Intima-Media Thickness in Type 2 Diabetic Patients
2009
De novolipogenesis in the liver in health and disease: more than just a shunting yard for glucose
2015
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
2013
Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
2013
Genes Involved in Fatty Acid Partitioning and Binding, Lipolysis, Monocyte/Macrophage Recruitment, and Inflammation Are Overexpressed in the Human Fatty Liver of Insulin-Resistant Subjects
2007
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
2017
A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP ‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients
2016
The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta‐analysis
2013
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Diabetes and Cancer
2010 Standout
Combination therapy with GLP ‐1 receptor agonists and basal insulin: a systematic review of the literature
2012
Overfeeding Polyunsaturated and Saturated Fat Causes Distinct Effects on Liver and Visceral Fat Accumulation in Humans
2014
Paratuberculosis
1994
Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?
2019 Standout
Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function
2011
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Adipose Tissue Inflammation and Increased Ceramide Content Characterize Subjects With High Liver Fat Content Independent of Obesity
2007
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
2010
Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity
2016 Standout
Review: Mitochondrial medicine--cardiomyopathy caused by defective oxidative phosphorylation.
2003
Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus
2015
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
2014 Standout
International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm
2011
Fatty Liver
2007
Treatment of Obesity in Mitigating Metabolic Risk
2020
Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
2011
The molecular mechanisms of pancreatic β-cell glucotoxicity: Recent findings and future research directions
2012
β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
2014
Dietary Carcinogens and Anticarcinogens
1983 StandoutScience
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
Mechanisms of Diabetic Complications
2013 Standout
Human Fatty Liver Disease: Old Questions and New Insights
2011 StandoutScience
The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function
1984
Lethal mitochondrial cardiomyopathy in a hypomorphic Med30 mouse mutant is ameliorated by ketogenic diet
2011 StandoutNobel
Metabolism of very long-chain monounsaturated fatty acids (22:1) and the adaptation to their presence in the diet.
1982
Optimized Human Regular U-500 Insulin Treatment Improves β-Cell Function in Severely Insulin-Resistant Patients with Long-Standing Type 2 Diabetes and High Insulin Requirements
2015
The Immunology of Mycobacterial Infections
1982
Nonalcoholic Fatty Liver Disease
2015 Standout
Glucagon‐like peptide‐1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta‐analysis
2016
Recovery of Altered Fatty Acid Composition Induced by a Diet Devoid of n‐3 Fatty Acids in Myelin, Synaptosomes, Mitochondria, and Microsomes of Developing Rat Brain
1986 StandoutNobel
Presentation of mycobacterial antigens by human dendritic cells: lack of transfer from infected macrophages
1993 StandoutNobel
Works of A. H. Corner being referenced
Nonalcoholic Fatty Liver Disease: Detection of Elevated Nicotinamide Adenine Dinucleotide Phosphate with in Vivo 3.0-T31P MR Spectroscopy with Proton Decoupling
2010
Increased expression of the macrophage markers and of 11β-HSD-1 in subcutaneous adipose tissue, but not in cultured monocyte-derived macrophages, is associated with liver fat in human obesity
2007
Acute in vivo effects of insulin on gene expression in adipose tissue in insulin-resistant and insulin-sensitive subjects
2005
One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress
2010
Insulin regulation of MCP-1 in human adipose tissue of obese and lean women
2008
Maedi Visna in Canadian Sheep
1980
The effect of dietary fatty acids on the incidence of cardiac lesions and changes in the cardiac phospholipids in male rats
1981
Evaluation of the serological response of sheep in one flock to Mycobacterium paratuberculosis by crossed immunoelectrophoresis.
1988
Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
2011
Chromatographic purification and characterization of antigens A and D from Mycobacterium paratuberculosis and their use in enzyme-linked immunosorbent assays for diagnosis of paratuberculosis in sheep
1991
Studies on Pathogenic Porcine Enteroviruses: 1. Preliminary Investigations.
1961
A Hemagglutinating Virus Producing Encephalomyelitis in Baby Pigs.
1962
Beneficial Changes on Body Composition and Circulating Adiponectin and hsCRP Levels Following One Year of Exenatide Therapy, Compared with Insulin Glargine, in Metformin-Treated Patients with Type 2 Diabetes
2009
Role of Dietary Saturated Fatty Acids on Lowering the Incidence of Heart Lesions in Male Rats
1982
Extended, 3-year, exenatide therapy shows sustainable effects on beta cell disposition index in metformin treated patients with type 2 diabetes
2010
Growth, Lipid Metabolism and Pathology of Two Strains of Rats Fed High Fat Diets
1979
Reduction of myocardial necrosis in male albino rats by manipulation of dietary fatty acid levels
1982
Liver Fat Is Increased in Type 2 Diabetic Patients and Underestimated by Serum Alanine Aminotransferase Compared With Equally Obese Nondiabetic Subjects
2007
Bovine paratuberculosis I. A herd study using complement fixation and intradermal tests.
1980
One Year Exenatide Therapy, Compared with Insulin Glargine, Reduces Postprandial Oxidative Stress in Metformin-Treated Patients with Type 2 Diabetes
2009
Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition
2010
Growth Rate, Lipid Composition, Metabolism and Myocardial Lesions of Rats Fed Rapeseed Oils (Brassica campestris var. Arlo, Echo and Span, and B. napus var. Oro)
1973
Cardiac lesions in rats fed rapeseed oils.
1975
One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients
2009